Corcept Therapeutics Financial Ratios
NASDAQ: CORTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Corcept Therapeutics ratio analysis
Corcept Therapeutics earned a net margin of 13.1% in FY 2025, down from 20.9% a year earlier. Gross margin was 98.3% compared with a median of 98.4% over the prior 9 years. Return on equity reached 15.4%, meaning Corcept Therapeutics generated 0.15 dollars of profit for every dollar of shareholders' equity.
At the end of FY 2025, CORT traded at 46.6 times earnings; across the 10 fiscal years shown, its year-end P/E ranged from 15.8 to 103.7, with a median of 27.1. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Corcept Therapeutics financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 46.59 | 41.35 | 34.55 | 23.34 | 22.25 | 30.78 | 15.75 | 23.03 | 17.37 | 103.71 |
| Price / sales | 5.21 | 7.78 | 6.97 | 5.40 | 6.26 | 8.53 | 4.53 | 6.34 | 12.88 | 9.87 |
| Price / book | 6.12 | 7.73 | 6.64 | 4.32 | 6.09 | 5.77 | 3.74 | 5.78 | 10.74 | 19.40 |
| Gross margin | 98.3% | 98.4% | 98.7% | 98.7% | 98.6% | 98.4% | 98.2% | 97.9% | 97.8% | 97.5% |
| Operating margin | 5.9% | 20.3% | 22.2% | 28.0% | 34.0% | 36.2% | 36.4% | 35.6% | 33.2% | 12.5% |
| Net margin | 13.1% | 20.9% | 22.0% | 25.2% | 30.7% | 30.0% | 30.7% | 30.0% | 81.1% | 10.0% |
| Free cash flow margin | 18.6% | 29.1% | 26.2% | 29.8% | 45.7% | 42.6% | 44.1% | 45.9% | 38.0% | 22.4% |
| Return on equity (ROE) | 15.4% | 20.8% | 20.9% | 20.2% | 29.9% | 20.3% | 25.4% | 27.3% | 67.6% | 19.7% |
| Return on assets (ROA) | 11.9% | 16.8% | 17.1% | 17.4% | 26.6% | 18.5% | 22.8% | 24.2% | 58.5% | 11.8% |
| Debt / equity | — | — | — | — | — | — | — | — | 0.00 | 0.35 |
| Current ratio | 2.92 | 3.35 | 4.39 | 6.89 | 5.60 | 10.07 | 7.91 | 6.66 | 4.20 | 2.40 |
| Revenue growth | 12.8% | 39.9% | 20.0% | 9.8% | 3.4% | 15.5% | 22.0% | 57.8% | 95.8% | 61.7% |
| EPS growth | -33.3% | 30.9% | 8.0% | -2.2% | 4.7% | 10.4% | 28.3% | -42.3% | 1,385.7% | — |